The integration of GLP-1 receptor agonists into autoimmune treatment has yielded partial improvements in disease control, not complete remission
Supporting better blood sugar control
According to FDA labeling and American Diabetes Association guidelines, GLP-1 receptor agonists are indicated for type 2 diabetes (as an adjunct to diet and exercise) and for chronic weight management in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
They're designed to: Confirm the weight loss and metabolic benefits seen in Phase 2 Identify rare side effects that smaller trials might have missed Demonstrate consistent results across diverse populations (age, sex, ethnicity, comorbidities) Build long-term safety data (cardiovascular outcomes, liver health, kidney function) Provide the evidence package the FDA needs to approve the drug Retatrutide's Phase 2 results were strong enough (up to 24.2% weight loss) that Eli Lilly moved it into a large Phase 3 program
The violent agitation and shearing forces can fracture the peptide bonds or cause the molecules to aggregate into useless clumps
Hot foods release more aroma compounds that trigger nausea compared to cold foods
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
